Omeprazole promotes proximal duodenal mucosal bicarbonate secretion in humans

A Mertz-Nielsen, J Hillingsø, K Bukhave, J Rask-Madsen

Abstract
The proton pump inhibitor, omeprazole, surprisingly resulted in higher rates of proximal duodenal mucosal bicarbonate secretion than previously reported using an H₂ receptor antagonist for gastric acid inhibition. Gastroduodenal perfusions were performed in healthy volunteers to evaluate whether this incidental finding is explained by more potent gastric acid inhibition by omeprazole or might be caused by the different mode of drug action. Basal and stimulated gastric and duodenal bicarbonate secretion rates were measured in the same subjects in control experiments (n=17) and after pretreatment with high dose omeprazole (n=17) and ranitidine (n=9), respectively, by use of a technique permitting simultaneous measurements. Concentrations of bicarbonate were measured in the respective effluents by the method of back titration. Both omeprazole and ranitidine completely inhibited gastric acid secretion (pH 6.9 vs 6.8; p>0.05). Omeprazole caused higher rates of basal (mean (SEM)) (597 (48) vs 351 (39) μmol/h; p<0.02) and vagally stimulated (834 (72) vs 474 (66) μmol/h; p<0.02), but not acid stimulated (3351 (678) vs 2550 (456) μmol/h; p>0.05) duodenal bicarbonate secretion compared with control experiments. Also the combination of omeprazole and ranitidine increased (p=0.05) duodenal bicarbonate secretion, while ranitidine alone caused no change in either basal or stimulated secretion. In the stomach basal as well as vagally stimulated bicarbonate secretion was independent of the means of acid inhibition. These results show that the proton pump inhibitor, omeprazole, promotes proximal duodenal mucosal bicarbonate secretion apparently independent of its gastric acid inhibitory effect. The mechanism of action remains speculative.

(Gut 1996; 38: 6–10)

Keywords: bicarbonate secretion, duodenum, omeprazole, stomach, ranitidine.

Previous work has shown the existence of a pH gradient at the luminal surface of the gastroduodenal mucosa generated by active secretion of bicarbonate into the mucus gel layer.1,2 As bicarbonate comprises the first line of defence against luminal acid and pepsin, recent research has focused on mucosal bicarbonate transport mechanisms both in experimental animals and in humans.3 The effect of various antulcer drugs on gastroduodenal bicarbonate secretion has been investigated in several studies,4 among which a few have concentrated on the effect of the proton pump inhibitor, omeprazole. Administration of omeprazole to cats has resulted in both reduced5 and increased6 rates of gastric bicarbonate secretion, while duodenal mucosal bicarbonate secretion in cats7 and in rats8 seems unaffected. Although relevant for clinical use in the treatment of acid related disorders, the potential effect of proton pump inhibitors on human gastroduodenal mucosal bicarbonate secretion has not previously been considered.

Incidentally, we observed that omeprazole resulted in higher rates of basal and vagally stimulated proximal duodenal mucosal bicarbonate secretion than previously reported using ranitidine as an inhibitor of gastric acid. To evaluate whether this finding might be explained by more potent inhibition of gastric acid by omeprazole or by the different mode of drug action, gastric and duodenal bicarbonate secretion rates were determined by use of a technique permitting simultaneous measurements.8 The same healthy volunteers were studied in control experiments without acid inhibition and after administration of omeprazole and ranitidine, respectively, using supramaximal, equipotent doses sufficiently large to obtain total inhibition of gastric acid secretion. In supplementary experiments, the combination of omeprazole and ranitidine on basal duodenal mucosal bicarbonate secretion was studied.

Methods

Healthy volunteers
Twenty one healthy volunteers (12 men and nine women, median age 32 years, range 24–50), with no history of gastrointestinal or other medical diseases, consented to the study protocol. None of the healthy volunteers had ingested aspirin, non-steroidal anti-inflammatory drugs, or alcohol during the week before
entering the study, which was carried out according to the Helsinki II Declaration and approved by the ethics committee of Copenhagen and Frederiksberg.

Experimental design

Three series of experiments were performed. In the first series eight volunteers had simultaneous gastric and proximal duodenal perfusions twice (isotonic saline) with an interval of at least one week. The perfusions were performed in random order, that is, as one set of control perfusions (without acid suppression for determination of acid secretion in the stomach and bicarbonate secretion in the duodenum) and one set of experimental perfusions (for determination of bicarbonate secretion in the stomach and the duodenum) prior to which the subject was pretreated with a 60 mg oral dose of omeprazole (Astra A/S, Albertslund, Denmark) once daily for three days and 80 mg intravenously one hour before perfusion.

In the second series of experiments nine other volunteers had gastric and proximal duodenal perfusion three times. The perfusions were performed in random order and included one set of control perfusions (without acid suppression) and two sets of experimental perfusions prior to which the subject was pretreated with omeprazole as described above or with a 900 mg oral dose of ranitidine (Glaxo Denmark A/S, Brøndby, Denmark) 12 and two hours before the experiment and ranitidine 50 mg/h intravenously during perfusion.

Supramaximal doses of omeprazole and ranitidine were chosen to ensure the complete suppression of gastric acid secretion required for determination of gastric bicarbonate secretion.9 Each perfusion in the first and second series of experiments included a 60 minute equilibration period followed by a 30 minute basal period and a 60 minute sham feeding period. In the second series of experiments the duodenal bulb was acidified (HCl 0·1 M; 20 ml; 5 min) after the sham feeding period and then the duodenum was perfused for 45 minutes with isotonic saline. Attempts to measure gastric bicarbonate secretion after acidification of the stomach failed, because it was impossible to remove all the instilled acid within 30 minutes.

In the third series of experiments another four healthy volunteers had proximal duodenal perfusion once to study the effect of the combination of omeprazole and ranitidine. Each subject was pretreated with omeprazole as described above and after a 60 minute equilibration period the duodenum was perfused during basal conditions for 60 minutes. Then a 50 mg intravenous bolus injection of ranitidine was given. After a 30 minute equilibration period the duodenum was perfused for another 60 minutes during basal conditions. Ranitidine 50 mg/h was given intravenously during this final 90 minute period.

Analytical procedures

Concentrations of hydrochloric acid in the gastric effluents from control experiments were determined by titration to pH=7·0 with 0·1 M NaOH (PHM82, Radiometer, Copenhagen, Denmark).

Concentrations of bicarbonate in 100 µl aliquots from gastric and duodenal effluents were determined in triplicate (Corning 965 Carbon Dioxide Analyzer, Corning Ltd, Hailstead, England).12 Before analysis the samples were gassed with CO2 free nitrogen for five minutes to remove dissolved carbon dioxide. The Corning analyser was calibrated daily against 2·5 and 5·0 mM NaHCO3. The coefficients of variation were 12% (n=20) and 6% (n=20), respectively.

To determine the contamination of the...
TABLE I  Basal gastric and duodenal pH measurements in 17 healthy volunteers during control conditions and after administration of omeprazole and ranitidine; mean (SEM)

<table>
<thead>
<tr>
<th></th>
<th>Stomach pH</th>
<th>Duodenum pH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>2.32 (0.11)</td>
<td>7.40 (0.12)</td>
</tr>
<tr>
<td>Omeprazole</td>
<td>6.87 (0.08)</td>
<td>7.27 (0.06)</td>
</tr>
<tr>
<td>Ranitidine</td>
<td>6.82 (0.09)</td>
<td>7.33 (0.11)</td>
</tr>
</tbody>
</table>

DUodenal test segment with pancreatic juice, trypsin was measured in the duodenal effluents as previously described.10

Activities of $^{51}$Cr and concentrations of phenol red were determined both in gastric and duodenal effluents and served as markers for recovery and contamination of the respective test segment. Activities of $^{51}$Cr were measured by gammadensitometry (Model 1185, Searle Nuclear Chicago Division, Chicago, IL, USA). Concentrations of phenol red were measured spectrophotometrically at 560 nm after alkalinisation (pH = 11) by a 4:1 dilution with a 0.5 M Na$_3$PO$_4$ solution.

Calculations and statistical analyses
Rates of acid and bicarbonate secretion were calculated as the mean of the two or four 15 minute values obtained during the basal periods. Similarly, the results obtained after stimulation were calculated as the mean of the three five minute values obtained in the stomach and the first 15 minute value obtained in the duodenum after start of modified sham feeding and as the mean of all values obtained in the duodenum after luminal acidification.

The results were expressed as means (SEM). The bicarbonate data were analysed using repeated measures analysis of variance (RMANOVA) for a two way model. The normality assumption for this model was tested with the Kolmogorov-Smirnov statistics. The Levene’s statistic was used to test for equal variance.13 For most of the end points the normality assumption was violated. Thus, RMANOVA was performed on ranks. Student-Newman-Keuls multiple comparison test was used for statistical analyses. Comparison of recoveries, contamination, and pH values were performed with Student’s t test for paired variates. All p values calculated were two tailed; the α value of significance was set at 0.05.

Results
Validation of methods
The mean recovery of the gastric and duodenal markers were 82 (2)% and 86 (2)%, respectively, with no differences between control, omeprazole, and ranitidine experiments. Values of basal and stimulated gastric and duodenal fluid outputs, in addition to recoveries of phenol red, $^{51}$Cr and trypsin, showed no significant differences (p>0.05) between the groups. Only a small amount of gastric contents entered the duodenum (0.3 (0.1)%), that is 0.01 ml/min. The duodenalgastric reflux was 0.8 (0.2)%, that is 0.06 ml/min. The contents of trypsin in the duodenal effluents were 0.6 (0.2)% of the average minimum trypsin output from the pancreas14 and a total of 11 samples from five subjects containing ≥25 µg/ml, 3% were excluded.

pH Measurements
Total inhibition of gastric acid secretion was achieved both after omeprazole and ranitidine administration and there was no significant difference between gastric pH values (p=0.06; Table I). The duodenal pH measurements showed no significant (p>0.05) differences between control, omeprazole and ranitidine experiments, respectively (Table I).

Gastric acid and bicarbonate secretion
In control experiments basal and vagally stimulated gastric acid secretion was 4.2 (1.1) mmol/h and 7.9 (1.7) mmol/h, respectively.

The basal rates of gastric bicarbonate secretion were 401 (56) µmol/h and 104 (40) µmol/h after ranitidine and omeprazole administration, respectively. The difference was not statistically significant (p>0.05; Table II). Modified sham feeding for 15 minutes caused a considerable rise (p<0.05) in bicarbonate secretion both in ranitidine, and in omeprazole experiments (Table II).

Proximal duodenal bicarbonate secretion
The basal rates of duodenal mucosal bicarbonate secretion in control and ranitidine experiments were 351 (39) µmol/h and 363 (63) µmol/h, respectively. In experiments with omeprazole the basal rate of proximal duodenal mucosal bicarbonate secretion was 597 (48) µmol/h (p<0.02) compared with control and ranitidine experiments, respectively (Table II and Figure).

Modified sham feeding for 15 minutes caused a moderate, but significant (p<0.05), rise in bicarbonate secretion in all experiments. The response to modified sham feeding after omeprazole administration was significantly

* p<0.05 compared with basal values; † p<0.02 compared with control and ranitidine (Student-Newman-Keuls’s test); ‡ p=0.05 compared with control (Student’s t test).

TABLE II  Effect of ranitidine, omeprazole, and the combination of omeprazole and ranitidine (Ome+Ran) on gastric and proximal duodenal mucosal bicarbonate secretion rates in healthy volunteers during basal conditions and after stimulation with modified sham feeding and luminal acid (0.1 M; 20 ml; 5 min); mean (SEM)

<table>
<thead>
<tr>
<th>Gastric HCO$_3^-$ (µmol/h)</th>
<th>Duodenal HCO$_3^-$ (µmol/h×3 cm)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Number</td>
</tr>
<tr>
<td>Control</td>
<td>17</td>
</tr>
<tr>
<td>Ranitidine</td>
<td>9</td>
</tr>
<tr>
<td>Omeprazole</td>
<td>17</td>
</tr>
<tr>
<td>Ome+Ran</td>
<td>4</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gastric HCO$_3^-$ (µmol/h)</th>
<th>Duodenal HCO$_3^-$ (µmol/h×3 cm)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Number</td>
</tr>
<tr>
<td>Control</td>
<td>17</td>
</tr>
<tr>
<td>Ranitidine</td>
<td>9</td>
</tr>
<tr>
<td>Omeprazole</td>
<td>17</td>
</tr>
<tr>
<td>Ome+Ran</td>
<td>4</td>
</tr>
</tbody>
</table>
The effects of omeprazole (■) and ranitidine (□) on basal and stimulated (modified sham feeding=MSF; acid load=HCI) proximal duodenal mucosal bicarbonate secretion in healthy volunteers compared with no treatment (○—○); mean (SEM). *p<0.02 compared with control and ranitidine (Student-Newman-Keul's multiple comparison test).

(p<0.02) higher than that seen in control and ranitidine experiments, respectively (Table II). Luminal acidification of the duodenal bulb caused a considerable rise in bicarbonate secretion in all experiments. No significant differences in response were seen between control, omeprazole, and ranitidine experiments (Table II).

The basal rates of proximal duodenal bicarbonate secretion in the third series of experiments were 513 (93) μmol/h after omeprazole alone and 528 (78) μmol/h after the combination of omeprazole and ranitidine (p>0.05; Table II).

Discussion

The results of this study show that the proton pump inhibitor, omeprazole, promotes proximal duodenal mucosal bicarbonate secretion, but not gastric bicarbonate secretion, in healthy volunteers, apparently independent of its acid inhibitory effect. While basal and sham feeding stimulated transport rates of bicarbonate in the duodenum were significantly higher in omeprazole experiments than in control and ranitidine experiments, it cannot be excluded that a type II error occurred when testing the results obtained during luminal acidification caused by a large variation between subjects.

The basal rates of gastric bicarbonate secretion seen in ranitidine and omeprazole experiments were in the same order of magnitude as those previously reported by others.9 15 Similarly, the rates of basal and stimulated proximal duodenal mucosal bicarbonate secretion seen in control and ranitidine experiments were similar to those obtained by others using the same six channel tube with three occluding balloons.12 16

The overall results of this study are, however, difficult to reconcile with much of the existing body of data relating to the action of omeprazole, considering that the compound is a highly specific, irreversible inhibitor of H⁺,K⁺ adenosine triphosphatase (ATPase), which blocks acid secretion in response to all modes of stimulation.17 H⁺,K⁺ ATPase inhibition has been reported to modulate ion transport in the small intestine of some amphibia,18 but this does not seem to occur in mammals.7 8 The mechanism responsible for the unexpected finding remains, therefore, obscure and theoretical considerations are speculative.

Nevertheless, omeprazole, compared with ranitidine, could inhibit acid secretion from heterotopic parietal cells in the duodenum,19 20 with abnormal or lacking H₂ receptors and thus seem to stimulate bicarbonate secretion. This is compatible with the finding that the combination of omeprazole and ranitidine resulted in the same rates of proximal duodenal mucosal bicarbonate secretion as omeprazole alone.

Omeprazole might also act to increase bicarbonate secretion indirectly by influencing the distribution of bicarbonate in the tissue, the mucosal blood flow, motility, or local nerves, while a role of Helicobacter pylori is unlikely in this paired design study. The possibility that omeprazole modulates neural reflexes would explain the discrepancy between results obtained in anaesthetised animals5-8 and conscious humans.

The possibility that duodenal bicarbonate secretion is inhibited by ranitidine, rather than promoted by omeprazole, should also be considered. If that was the case, histamine H₂ receptor antagonists might be expected to decrease bicarbonate secretion both in the stomach and in the duodenum. Acid inhibition by supramaximal doses of ranitidine did not modulate gastric bicarbonate secretion, however, either in this study or in previous studies of healthy volunteers5 14 and duodenal mucosal bicarbonate secretion has been shown to be unaffected by ranitidine in animals.7 8 The apparent lack of effect of ranitidine could also be taken to imply that leakage of gastric acid occurred in control experiments despite the presence of occluding balloons. The rate of neutralised bicarbonate, however, as calculated from the appearance of the gastric marker in the duodenal effluents, did not exceed 20 μmol/h.

In conclusion, our results show that omeprazole promotes proximal duodenal mucosal bicarbonate secretion, but do not support the notion that histamine H₂ receptor blockade inhibits mucosal bicarbonate secretion. While the normal basal output of bicarbonate from the duodenum equals approximately 1000 μmol/h (duodenum about 9 cm; see Table II), or 25% of basal gastric acid secretion, the omeprazole induced duodenal bicarbonate output amounts to approximately 1800 μmol/h, or 40% of basal gastric acid secretion, which could be neutralised by this alkali. Thus, the observed increase in duodenal neutralising capacity caused by omeprazole is likely to add to the well documented superiority of omeprazole (compared with histamine H₂ receptor antagonists) in duodenal ulcer healing.
Part of this work was presented at the Annual Meeting of the American Gastroenterological Association in May 1994 in New Orleans (Gastroenterology 1994; 106: A138) and was supported by a research grant from Astra A/B Mölndal, Sweden. The skillful technical assistance by Benedicte Bukhave is gratefully acknowledged.